The Mesoblast (ASX:MSB) share price is getting attention following the company’s latest capital raise. Here’s a bit more background.
The post What’s weighing on the Mesoblast (ASX:MSB) share price lately? appeared first on The Motley Fool Australia. –
The Mesoblast Limited (ASX: MSB) share price has dipped 0.43% at the time of writing and is currently trading at $2.31 a share. This compares to the S&P/ASX200 Index (ASX: XJO), which has jumped 1.75% so far today.
In fact, over the past four months the Mesoblast share price has fallen more than 40%. So what’s going on?
Why is the Mesoblast share price going down?
Mesoblast carried out a capital-raising exercise, which was announced last week. The cash injection came just in time, as concerns about Mesoblast’s dwindling cash flow have been weighing on the company’s share price over the past few months.
On 28 February 2021, the Australian Financial Review quoted the auditor of Mesoblast’s latest results, who stated that, “material uncertainty exists that may cast significant doubt on the group’s ability to continue as a going concern”.
For the 6-month period ended 31 December 2020, Mesoblast posted a loss of $33.2 million and the company’s deficit stood at US$599 million.
So what does the capital deal look like?
Mesoblast raised US$110 million issuing 60 million shares at A$2.30 in a private placement led by a US investor group.
The money will be used to keep pushing the company’s products through the necessary United States Food and Drug Administration (FDA) approvals in the second and third quarters. For example, work will continue on gaining US regulatory approvals pertaining to a back pain treatment that uses Mesoblast’s rexlemestrocel-L drug.
Funding will also be allocated toward generally progressing its remestemcel-L and rexlemestrocel-L platforms.
The business advised that it will invest in a commercial supply of remestemcel-L and continue to advance the manufacturing and development of rexlemestrocel-L.
Mesoblast share price snapshot
Mesoblast has a market capitalisation of $1.4 billion and there are presently 623.5 million shares outstanding.
Over the past year, the Mesoblast share price has climbed by 26%.
The company is a developer of medicinal treatments for severe and life-threatening inflammatory conditions. It has locations in Australia, the United States and Singapore, and has commercialised two of its products in Japan and Europe.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- These are the 10 most shorted shares on the ASX
- ASX 200 up 0.3%: Mesoblast raises US$110 million, tech shares rebound
- Here’s why the Mesoblast (ASX:MSB) share price is tumbling lower today
- Did you know Piedmont (ASX:PLL) and Mesoblast (ASX:MSB) are listed on the NASDAQ?
- 5 things to watch on the ASX 200 on Tuesday
Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.